Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMENTUM: momelotinib versus danazol in symptomatic anemic myelofibrosis
MOH_2019-12-09_008544Phase 3Active, not recruiting
- Sponsor
- Sierra Oncology
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mivavotinib and danazol in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (2 arms), sponsored by Sierra Oncology. Started Oct 2019; status: active, not recruiting.
02
Drugs
mivavotinibdanazol
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on MOH_2019-12-09_008544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-09_008544.